<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472169</url>
  </required_header>
  <id_info>
    <org_study_id>2019_75</org_study_id>
    <secondary_id>2020-A00584-35</secondary_id>
    <nct_id>NCT04472169</nct_id>
  </id_info>
  <brief_title>UPLC-MS/MS Monitoring of Emicizumab Therapy</brief_title>
  <acronym>EMICARE</acronym>
  <official_title>Value of Emicizumab Monitoring With UPLC-MS/MS for Bleeding Risk Prediction in Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupement Interrégional de Recherche Clinique et d'Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emicizumab is a monoclonal bispecific antibody with a terminal half-life of 28 days which is&#xD;
      now licensed in the treatment of severe haemophilia A with or without inhibitors. Some&#xD;
      heterogeneity in residual emicizumab concentrations have been reported according to age, body&#xD;
      mass index or drug therapeutic regimen. Some cases of neutralizing antidrug antibodies have&#xD;
      been also reported. Whether monitoring emicizumab plasma concentration could predict the&#xD;
      residual bleeding risk under emicizumab is unknown. As conventional coagulation assays are&#xD;
      not adapted for emicizumab monitoring, this study aims to assess the value of monitoring&#xD;
      residual emicizumab plasma concentration by UPLC-MS/MS in bleeding risk prediction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve ROC of Residual plasma level of emicizumab</measure>
    <time_frame>At Week 5 (end of emicizumab loading period)</time_frame>
    <description>At least one clinically significant bleeding (defined as any bleeding treated with FVIII, rFVIIa or aPCC) from loading period completion (week 5) to the end of study, an average of 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab measured by UPLC-MS/MS</measure>
    <time_frame>At Week 5 (end of emicizumab loading period)</time_frame>
    <description>At least one hemarthrosis from loading period completion (week 5) to the end of study, an average of 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab measured by UPLC-MS/MS</measure>
    <time_frame>At each breakthrough bleeding until end of study</time_frame>
    <description>Post-traumatic or spontaneous nature of bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab (UPLC-MS/MS dosing)</measure>
    <time_frame>At Week 5 and at each breakthrough bleeding until end of study</time_frame>
    <description>Emicizumab FVIII-like activity (chromogenic FVIII BIOPHEN™assay system with emicizumab calibration)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Severe haemophila A patients with or without inhibitors</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, poor-platelet plasma, whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients with severe hemophilia A will be included in the study on 2 french Hemophilia&#xD;
        Treatement Centers (CHU Lille and CHU Caen)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult or child with Clinical diagnosis of severe hemophilia A (FVIII activity &lt; 1%)&#xD;
             with or without inhibitor&#xD;
&#xD;
          -  Clinical indication to emicizumab therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to give informed consent&#xD;
&#xD;
          -  acquired hemophilia A&#xD;
&#xD;
          -  other inherited or acquired bleeding disorder&#xD;
&#xD;
          -  bodyweight &lt; 10 kgs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>antoine.rauch@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yohann Repesse, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Antoine Rauch, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug monitoring</keyword>
  <keyword>Severe Hemophilia A</keyword>
  <keyword>Emicizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

